Palatin Technologies Unveils Breakthrough Preclinical Data for Oral Obesity Drug PL7737

Company demonstrates rapid weight loss in animal models with potential best-in-class oral MC4R therapy

Palatin Technologies (OTCQB: PTNT) (NYSE: PTN) has just released compelling preclinical efficacy data for PL7737, its oral selective melanocortin-4 receptor (MC4R) agonist, showing remarkable effectiveness in rodent obesity models that could reshape the competitive landscape in the rapidly expanding obesity therapeutics market.

The preclinical study evaluated PL7737 both as monotherapy and in combination with tirzepatide, a GLP-1/GIP agonist, in diet-induced obese rat models. After just four days of treatment, all results achieved statistical significance compared to vehicle control, with particularly impressive outcomes in combination therapy scenarios.

The high dose PL7737 monotherapy produced 10% weight loss, while the middle dose achieved 5% weight loss. When combined with tirzepatide, the results were even more striking. The PL7737 middle dose plus tirzepatide combination delivered 11% weight loss, and the high dose combination reached 15% weight loss. As a point of comparison, tirzepatide alone produced 5% weight loss.

The rapid onset and substantial weight reduction observed in these established animal models suggests significant potential for meaningful clinical efficacy in humans. Most notably, the combination therapy demonstrated additive effects, with PL7737 enhancing tirzepatide’s efficacy beyond what either drug achieved alone.

“The rapid and significant weight loss seen with oral PL7737, both as monotherapy and in combination with tirzepatide in this established animal model, is impressive and suggests the potential for meaningful weight reduction in humans,” said Carl Spana, Ph.D., President and CEO of Palatin.

Strategic Market Positioning

PL7737 represents a unique approach in the obesity therapeutics space, targeting the MC4R pathway, a mechanism distinct from the incretin-based therapies that currently dominate the market. With only one other company, Rhythm Pharmaceuticals with a market cap of approximately $5.8 billion, actively pursuing MC4R-targeted obesity treatments, Palatin appears well-positioned to capture significant market share in this underexplored therapeutic area.

The company has received FDA orphan drug designation for PL7737 in treating obesity due to leptin receptor deficiency, a rare genetic condition, and is also evaluating the compound for hypothalamic obesity in both acquired and congenital forms.

Development Timeline and Catalysts

Palatin’s IND-enabling toxicology program is currently ongoing, with IND submission planned for the fourth quarter of 2025. The company expects to initiate Phase 1 single- and multiple-ascending dose clinical trials in late 2025, with topline data anticipated in the first half of 2026.

Critically, the Phase 1 studies will include patients with hypothalamic obesity, representing a significant unmet medical need with no currently approved pharmacologic treatments. This rare and severe form of obesity, caused by dysfunction or damage to the hypothalamus, affects patients who typically experience rapid, excessive weight gain and uncontrollable hunger that is resistant to conventional interventions.

The company is simultaneously advancing selective peptide MC4R agonists designed for weekly subcutaneous administration, providing multiple development pathways within the MC4R approach and flexibility to target both general obesity and rare forms of the disease.

With obesity therapeutics representing a multi-billion dollar market opportunity and PL7737 offering a differentiated mechanism of action, Palatin’s upcoming clinical data could serve as a significant catalyst for the stock, particularly given the company’s current early-stage valuation relative to the potential market opportunity.

Palatin Technologies Unveils Breakthrough Preclinical Data for Oral Obesity Drug PL7737

Subscribe for updates

Read more Articles from The Finance Herald